Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOSFORMEN: Fosfomycin vs fluoroquinolones or cotrimoxazole in febrile male urinary tract infection
2026-525972-25-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fosfomycin in urinary tract infection (UTI) and bacterial prostatitis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary clinical cure at Day 26. Planned start Jul 2026; status: authorised.
02
Drugs
fosfomycin
03
Conditions
urinary tract infection (UTI)bacterial prostatitis
Beyond the preview
Go deeper on 2026-525972-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525972-25-00.